The company recorded a $5.6 billion charge in the third quarter related to Paxlovid and vaccine Comirnaty, most of which was disclosed earlier this month. Pfizer also said the experimental messenger-RNA influenza vaccine it was developing met both its primary goals in a late-stage study in 18- to 64-year olds. Sales of the COVID-19 pill and the vaccine it makes with German partner BioNTech SE had boosted Pfizer's revenue to record levels in the last two years.